The FDA confirms safety and efficacy of Pfizer covid vaccine

The US Food and Drug Administration confirms that data on Pfizer’s coronavirus vaccine is in line with its guidance on emergency use authorization, which the firm had requested. Pfizer cleared the latest hurdle in the race to get its Covid-19 vaccine vaccine developed with German pharmaceutical partner BioNTech approved for emergency use. FDA documents did not raise any new issues about its safety or efficacy ahead of the Thursday’s meeting by outside experts. They showed the vaccine provided protection after the first of two doses and two doses were “highly effective in preventing confirmed cases of covid-19 at least 7 days after the last dose.” But there was insufficient data for conclusions for the safety of the vaccine in people younger than 16, pregnant women and people whose immune system was compromised.

Print Friendly, PDF & Email